Researchers at The University of Tokyo and St. Jude Children’s Research Hospital have identified a previously unrecognized role for the mixed lineage kinase like (MLKL) protein in the aging of hematopoietic stem cells (HSCs). Contrary to its established association with necroptosis, the study reveals that MLKL activation damages mitochondria without inducing cell death, leading to impaired stem cell function and a weakened immune response. This finding was published in Nature Communications and highlights a novel mechanism by which aging affects HSCs.

The significance of this research lies in its potential to reshape our understanding of stem cell aging. As HSCs age, they exhibit reduced self-renewal capacity and an imbalance in blood cell production, favoring myeloid over lymphoid lineages. The study demonstrates that MLKL’s activation under stress conditions compromises mitochondrial integrity, thereby diminishing energy production and contributing to the aging phenotype of HSCs. Notably, the detrimental effects of MLKL can be mitigated by its inactivation, suggesting a pathway that could be targeted for therapeutic intervention.

The implications for aging research and clinical applications are profound. By elucidating the role of MLKL in mitochondrial damage and HSC aging, this work opens avenues for the development of mitochondrial-protective therapies or drugs that modulate necroptosis pathways. Such strategies could enhance the recovery of patients undergoing chemotherapy or transplantation by preserving HSC function and improving long-term health outcomes. This research not only challenges existing paradigms regarding cell death mechanisms but also underscores the importance of mitochondrial health in stem cell biology and aging.

Source: sciencedaily.com